SCHEMBL3354407

SCHEMBL3354407

CC[C@@]12CCC[C@H]1[C@@H]1CCC3=CC(=O)CC(C4CC4)[C@@H]3[C@H]1CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 6/20 0.38
▸ AR P10275 5/20 0.38
▸ CYP3A4 P08684 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ CYP19A1 P11511 2/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ SLC6A4 P31645 2/20 0.38
▸ SHBG P04278 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ ABCB11 O95342 1/20 0.38
▸ ESR1 P03372 1/20 0.38
▸ NR3C2 P08235 1/20 0.37
▸ SERPINA6 P08185 2/20 0.36
▸ SLC22A1 O15245 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10705595 0.87 SHBG (0.41) PGRARCYP3A4LMNACYP19A1
SCHEMBL3358546 0.86 PGR (0.40) PGRARCYP3A4LMNACYP19A1
SCHEMBL3356884 0.82 CYP19A1 (0.44) CYP3A4LMNACYP19A1SHBGCYP2C19
SCHEMBL9116613 0.80 CYP19A1 (0.60) PGRARCYP3A4LMNACYP19A1
SCHEMBL3643602 0.79 SHBG (0.35) PGRARCYP3A4LMNACYP19A1
SCHEMBL3645097 0.76 CYP19A1 (0.41) PGRARCYP3A4LMNACYP19A1
SCHEMBL4112981 0.75 PGR (0.38) PGRARCYP3A4LMNACYP19A1
SCHEMBL9948554 0.74 SERPINA6 (0.47) PGRARCYP3A4LMNACYP19A1
SCHEMBL9947825 0.71 CYP19A1 (0.42) PGRARCYP19A1SHBGNR3C2
SCHEMBL13372867 0.70 PGR (0.34) PGRARCYP3A4LMNACYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010066354-A1 USE OF 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR MANUFACTURING A MEDICAMENT IN A SUSTAINED-RELEASE FORM FOR PARENTERAL USE, AND SUSTAINED-RELEASE MEDICAMENT CONTAINING 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVES FOR PARENTERAL USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 — — WO disclosed
EP-2178899-A1 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE Bayer Schering Pharma Aktiengesellschaft (DE) 2010-04-28 — — EP disclosed
WO-2008151745-A1 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO disclosed
Send feedback